Epitalon (Ala-Glu-Asp-Gly) was introduced by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as a defined tetrapeptide fragment of Epithalamin, a polypeptide preparation extracted from bovine pineal glands. The research program around Epitalon has produced an unusually concentrated body of work from a single network of investigators, much of it published in Russian or in lower-impact international journals.
The central claim — that Epitalon induces expression of human telomerase reverse transcriptase (hTERT) in somatic cells — has substantial experimental support within the originating laboratory. Reported observations include hTERT mRNA up-regulation, elongation of telomeres in cultured fibroblasts and lymphocytes from elderly donors, and extension of mean lifespan in chronic-administration studies in mice and rats. Animal data also include modest improvements in melatonin secretion profiles, T-cell function, and tumor incidence.
The independent-replication picture is mixed. The general phenomenon of peptide-mediated transcriptional modulation is well established for other Khavinson peptides, but the specific telomerase-activation findings have not been broadly reproduced in Western academic settings. Critics have noted that the most consistent positive findings come from a relatively small set of laboratories, while attempts at independent confirmation have produced mixed results. The picture is further complicated by methodological inconsistencies in early studies, including variable dosing, route, and animal husbandry.
Epitalon is included in the PharmaKinetics database as a representative entry in the longevity-peptide class, with the understanding that the evidence base, while substantial in absolute terms, remains concentrated within a defined research community. It is not approved as a therapeutic in any major regulatory jurisdiction.